Rubius Therapeutics Common Stock

Rubius Therapeutics (RUBY) currently reports a common stock of $90K as of December 2022. That compares with $90K in the prior-year period — up 0.0% year over year. Use the charts on this page to explore Rubius Therapeutics's common stock history and peer comparisons.

Rubius Therapeutics's common stock was unchanged from $90K to $90K — essentially flat versus a year earlier (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Rubius Therapeutics reported $90K in common stock as of December 2022. That compares with $90K in the prior-year period — up 0.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current common stock of $90K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Rubius Therapeutics, and consider following RUBY for alerts when major investors trade the stock.

Rubius Therapeutics is classified in the Healthcare sector. On common stock, it currently shows $90K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RUBY with unrelated industries.